Study Confirms the Value of Cambridge Heart, Inc. (CAMH)’s MTWA Test as a Predictor of Life-Threatening Cardiac Events

6/6/2012 10:11:26 AM

TEWKSBURY, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today announced that results of a prospective, 155-patient trial reinforce the value of the Microvolt T-Wave AlternansTM (MTWA) test as a predictor of life-threatening heart rhythms and Sudden Cardiac Death (SCD). The results were published this week in the journal Kardiologia Polska.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• Cambridge Heart, Inc.

• Diagnostics

• Medical Dev. & Diag. - Product News